D81.30
Adenosine deaminase deficiency, unspecified
Clinical Classification Guidelines
Inclusion Terms
- ADA deficiency NOS
Medical Intelligence & Overview
Adenosine deaminase (ADA) deficiency is a rare genetic disorder that affects the immune system. It is classified under the ICD-10 code D81.30 and is characterized by a lack or deficiency of the enzyme adenosine deaminase. This enzyme plays a crucial role in the functioning of immune cells. When ADA levels are insufficient, it can lead to a compromised immune system, making individuals more susceptible to infections. ADA deficiency is often diagnosed in infancy or early childhood and can significantly impact a patient's health if not properly managed. While some cases are part of a broader spectrum of severe combined immunodeficiency (SCID), others may have a milder presentation.
Causes & Symptoms
Clinical Causes: Genetic mutations in the ADA gene leading to impaired production or function of the enzyme Inheritance of defective genes passed from parents (autosomal recessive inheritance)
Key Symptoms: Frequent, severe infections from bacteria, viruses, fungi, or other pathogens Persistent diarrhea and failure to thrive in infants Eczema or skin rashes Recurrent respiratory infections such as pneumonia or bronchitis Chronic infections that do not respond well to standard treatments Swelling or enlargement of lymph nodes and liver Delayed development and growth issues in children
Diagnostic & Treatment
Diagnosis Path: Diagnosing adenosine deaminase deficiency involves a combination of clinical evaluation and laboratory tests. Common diagnostic approaches include: - Blood tests to measure ADA enzyme activity levels - Genetic testing to identify mutations in the ADA gene - Immune system assessment to evaluate the number and functionality of immune cells, particularly lymphocytes - CBC (complete blood count) to detect abnormalities in blood cell counts Early diagnosis is critical for effective intervention and management. Pediatricians and immunologists often collaborate to establish the diagnosis, especially in children displaying recurrent infections and developmental delays.
Treatment Protocols: Management of ADA deficiency aims to restore immune function and prevent infections. Treatment options may include: - Enzyme replacement therapy with pegylated adenosine deaminase (Peg-Ada), which provides the missing enzyme - Hematopoietic stem cell transplantation (bone marrow transplant), potentially curative by replacing defective immune cells - Gene therapy, an emerging treatment aimed at correcting the genetic mutation - Supportive care such as infection prevention measures, antibiotics, and immunoglobulin replacement therapy - Regular monitoring by healthcare providers to assess immune status and adjust treatments accordingly Early and appropriate treatment can significantly improve the quality of life for patients with ADA deficiency and reduce the risk of life-threatening infections.
Clinical Advice & FAQs
Billing Guidance
Is D81.30 a billable ICD-10 code?
Yes, D81.30 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D81.30?
Clinical documentation must specify the nature of Adenosine deaminase deficiency, unspecified and any associated comorbidities for accurate reporting.
Cite this Clinical Reference